GERMANTOWN, Md., Jan. 13, 2016 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced that Samuel Broder, M.D., Senior Vice President and Head of Intrexon's Health Sector, will present today at 8:30 a.m. Pacific Standard Time at the 34(th) Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco. Chairman and Chief Executive Officer Randal J. Kirk and Chief Operating Officer Krish Krishnan will also participate in the conference.

http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO

Dr. Broder will provide an overview of Intrexon's platforms for developing next-generation gene and cell therapies, as well as an update on projected milestones for the Company and its health sector collaborators in 2016 which include up to eight potential Investigational New Drug applications and clinical trial initiations within the fields of oncology, ocular therapy, rare skin disorders and infectious diseases. He will also discuss recent developments related to the Intrexon/Oxitec vector control technology and the new paradigm emerging to protect people from mosquito-borne diseases.

A live webcast of the presentation will be available on the Investors section of Intrexon's website at http://investors.dna.com/events. A replay of the webcast will be available for 30 days following the event.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA((TM)) to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA(®), and we invite you to discover more at www.dna.com or follow us on Twitter @Intrexon.

Trademarks

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information regarding Intrexon Corporation:

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com

Logo - http://photos.prnewswire.com/prnh/20130919/NY83283LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intrexon-announces-presentation-at-the-34th-annual-jp-morgan-healthcare-conference-300203698.html

SOURCE Intrexon Corporation